LearnGlossaryMarketStocksSuperinvestorsSign in

PVLA

Palvella Therapeutics, Inc.

Healthcare · $2.2B market cap

Verdict

We can't put a fair value on PVLA right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-55.4% a year✗
Sales growth-17.6% a year✗
Free cash flow growth—?
Return on invested capital-49.3%✗

Follow PVLA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 2, 2026: no open-market purchases, 1 sale worth $49K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

KIRITSY CHRISTOPHER P

director · 2026-09-02

Sold

$49K

Other filings

KIRITSY CHRISTOPHER P

director · 2026-09-02

Option exercise

$40K

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works